Global Discovery Biosciences


Lung cancer is the leading cause of cancer death worldwide, lung cancer accounts for 12.7% of diagnosed cancers and 18.2% of cancer deaths

Typically, the symptoms of lung cancer appear at an advanced stage of cancer, where the chance of a cure has already passed. Approximately 75% of lung cancers are diagnosed at an advanced stage.4 Early screening is a preferred solution, yet to date, no method for lung cancer screening has proven effective.

GD Biosciences, in collaboration with IPMD, Inc., is developing a simple and highly accurate blood test for the early detection of lung cancer as a solution that addresses the current lack of standard screening procedures.

Our affordable, non-invasive aptamer-based lung cancer screening solution analyzes the plasma protein profile from a small sample of patients’ blood using a revolutionary hypernetwork algorithm. Our goal is to apply this revolutionary technology to aid in the diagnosis of other leading cancers.

Heart Disease

Heart Disease

Coronary Heart Disease (CHD) is the major cause of morbidity and mortality despite recent improvements in cardiac disease management

Current diagnostic and clinical risk stratification tools that rely on established risk factors do not fully estimate the incidence and prevalence of CHD. In fact, over 50% of individuals presenting with a severe cardiac event have at most one risk factor or normal cholesterol levels.

The latest research shows that most heart attacks (75%) are caused by “unstable lesions” that form in the wall of the artery and eventually rupture - causing the blood to clot and prompting a heart attack.

After 15 years of research, GD Biosciences has successfully addressed unstable lesions with the PULS™ (Protein Unstable Lesion Signature) Test, which measures the biological processes underlying unstable lesion formation and rupture. The can help physicians identify vulnerable patients early-on, and implement critical prevention strategies.

Collaboration Opportunities

Collaboration Opportunities

If you would like to work with us in a particular research area, or if you are interested in commercializing your colinical product please submit a proposal.

*Data based on 2010 CDC Deaths and Mortality

1 Sachdeva, et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. AHJ. 2009; 157; Issue 1.

2 Hill S, et al. Absolute risk representation in cardiovascular disease prevention: Comprehension and preferences of health care consumers and general practitioners involve in a focus group study. BMC Public Health. 2010; 10:108.

3 Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010 Dec 15;127(12):2893-917.

4 Riess, J. Shifting Paradigms in Non-Small Cell Lung Cancer: An Evolving Therapeutic Landscape. 2013 Dec 30.

5 de Koning HJ, et al. Benefits and harms of lung cancer screening: modeling strategies for the U.S. Preventive Services Task Force. Ann Intern Med. 2013.

6 Infante M, et al; DANTE Study Group. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180(5):445-53.

7 Saghir Z, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296-301.